345 related articles for article (PubMed ID: 28473214)
1. Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes.
Chi C; Snaith J; Gunton JE
Heart Lung Circ; 2017 Nov; 26(11):1133-1141. PubMed ID: 28473214
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis.
McCormick TA; Kramer J; Liles EG; Amos Q; Martin JP; Adams JL
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38719507
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
4. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
Cheng JWM; Badreldin HA; Patel DK; Bhatt SH
Curr Med Res Opin; 2017 Jun; 33(6):985-992. PubMed ID: 28097882
[TBL] [Abstract][Full Text] [Related]
7. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
[TBL] [Abstract][Full Text] [Related]
9. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
10. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
11. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
Nassif ME; Kosiborod M
Am J Cardiol; 2019 Dec; 124 Suppl 1():S12-S19. PubMed ID: 31741435
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Lim S; Eckel RH; Koh KK
Atherosclerosis; 2018 May; 272():33-40. PubMed ID: 29547706
[TBL] [Abstract][Full Text] [Related]
13. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
Shin JI
Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
[TBL] [Abstract][Full Text] [Related]
14. Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.
Chang LS; Vaduganathan M; Plutzky J; Aroda VR
Curr Diab Rep; 2019 Dec; 19(12):157. PubMed ID: 31802265
[TBL] [Abstract][Full Text] [Related]
15. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Ferrannini E; DeFronzo RA
Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
Lim S; Kim KM; Nauck MA
Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
[TBL] [Abstract][Full Text] [Related]
17. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.
Basile JN
Hosp Pract (1995); 2016; 44(1):9-20. PubMed ID: 26781810
[TBL] [Abstract][Full Text] [Related]
18. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
Bonadonna RC; Borghi C; Consoli A; Volpe M
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
[TBL] [Abstract][Full Text] [Related]
19. A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials: Implications for practice.
Battise DM; Olin JL
J Am Assoc Nurse Pract; 2021 Mar; 33(12):1139-1147. PubMed ID: 33105320
[TBL] [Abstract][Full Text] [Related]
20. Updates on cardiovascular outcome trials in diabetes.
Schnell O; Rydén L; Standl E; Ceriello A;
Cardiovasc Diabetol; 2017 Oct; 16(1):128. PubMed ID: 29020969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]